Policy & Regulation
Ascletis Pharma receives Chinese approval for all-oral HCV treatment
31 July 2020 -

China-based Ascletis Pharma Inc (HKEX code: 1672) has received approval from the National Medical Products Administration (NMPA) for its all-oral Hepatitis C virus (HCV) treatment, for marketing in China, it was reported on Thursday.

The all-oral HCV treatment is Ravidasvir (Asclevir) in combination with Danoprevir (Ganovo).

The company's phase II/III clinical trial has indicated that the treatment regimen showed a 99% cure rate with a short treatment duration of 12 weeks in genotype one patients, and in patients with baseline NS5A resistance mutations, the treatment Regimen indicated a cure rate of 100% (SVR12). National Science and Technology Major Project has chosen both Ravidasvir and Danoprevir for 'Innovative Drug Development' programs. Presidio Pharmaceuticals Inc, a clinical stage pharmaceutical company, licensed Ravidasvir.

Login
Username:

Password:


Related Headlines